MADRID, 4 & # 39; December (EUROPA PRESS) –
The Quimatryx company is developing a Guipuzcoa, b & # 39; & # 39 collaboration with; Dr. Manel Esteller, an international expert in epigenetics and cancer, a new drug called & # 39; QTX125 & # 39; to treat & # 39; haematological cancers, such as mantle cell lymphoma or leukemia, plans to enter human clinical phase in early 2020.
Esteller presented the results of evaluation of medication in Congress of the American Society of Hematology (ASH, for its acronym in English). The data complement the findings obtained previously in & # 39; of mantle cell lymphoma, as in & # 39; this event was observed in & # 39; mobile models that "QTX125" compound has a high antitumoural activity against other types of & # 39; blood cancers, such as acute myeloid leukemia and B cell lymphoma
Currently, Quimatryx, also working on drugs against the disease & # 39; Alzheimer's, continues the regulatory preclinical phase of the compound & # 39; QTX125 & # 39 ;.